10 Jun 2026

CRC Research Update — June 10, 2026

Creator: The CRC Digest
Published: 2026-06-10T14:46:59Z

Today's colorectal cancer research highlights

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

Signal Key

TRIAL DATA clinical trial results, efficacy data, survival endpoints TREATMENT new treatment options, regimen changes, combination therapies REGULATORY FDA/EMA approvals, guideline updates, NCCN/ESMO changes RESEARCH cancer biology, biomarker discoveries, resistance pathways SCREENING screening, colonoscopy guidelines, liquid biopsy, molecular profiling LIVING WITH CRC survivorship, quality of life, side effects, patient decision-making, caregiver support

CRC Research Update

Study examines body mass index and survival in stage I-III colorectal cancer
A meta-analysis of 7,264 patients aimed to determine whether elevated BMI is directly associated with adverse survival in primary colorectal cancer, or indirectly through treatment-related mechanisms such as dose-capping adjuvant chemotherapy and toxicity. (British Journal of Cancer)
Blood-based Raman spectroscopy tested for colorectal cancer detection
A pilot study of 370 participants tested Raman spectroscopy combined with machine learning to detect CRC using plasma samples from 117 CRC patients and 253 iFOBT positive control participants. (ANZ J Surg)
BRAF V600E screening conducted for resectable colorectal oligometastases
A multicenter screening study evaluated preoperative BRAF V600E mutation screening in patients with resectable colorectal oligometastases for recruitment to a clinical trial investigating perioperative use of the BEACON triplet regimen. (Int J Clin Oncol)
Left-sided and right-sided colorectal cancers show distinct molecular drivers
Multi-omics analysis of 80 CRC patients revealed that left-sided tumors are predominantly driven by chromosomal instability, while right-sided cancers are primarily linked to microsatellite instability. (MedComm)

🔎 Screening Watch

Advances in early detection and screening strategies

Serrated lesions and colorectal cancers
A review highlights that sessile serrated lesions contribute disproportionately to right-sided interval cancers, with limited evidence guiding best practices for resection and surveillance. (Dig Endosc)
Shared decision-making training increases screening options
A cluster randomized trial in Switzerland found that training primary care physicians in shared decision-making promoted offering both colonoscopy and FOBT for CRC screening. (PLoS One)

🧬 Biomarker Spotlight

Research by genetic subtype — KRAS, BRAF, MSI-H, and more

BRAF V600E screening identifies candidates for perioperative therapy
Multicenter screening evaluated preoperative BRAF V600E mutation detection in patients with resectable colorectal oligometastases, enabling recruitment to a trial of the BEACON triplet regimen. (Int J Clin Oncol)

Today's research highlights progress in understanding how tumor location and biomarkers shape treatment strategies, alongside promising advances in blood-based screening. Stay informed, stay hopeful.

CRC Research Update

Subscribe to The CRC Digest